Back to Search
Start Over
Partial Loss of USP9X Function Leads to a Male Neurodevelopmental and Behavioral Disorder Converging on Transforming Growth Factor beta Signaling
- Source :
- Biological Psychiatry, 87, 100-112, Biological Psychiatry, 87, 2, pp. 100-112, Johnson, B V, Kumar, R, Oishi, S, Alexander, S, Kasherman, M, Vega, M S, Ivancevic, A, Gardner, A, Domingo, D, Corbett, M, Parnell, E, Yoon, S, Oh, T, Lines, M, Lefroy, H, Kini, U, van Allen, M, Grønborg, S, Mercier, S, Küry, S B, Bézieau, S, Pasquier, L, Raynaud, M, Afenjar, A, Billette de Villemeur, T, Keren, B, Désir, J, van Maldergem, L, Marangoni, M, Dikow, N, Koolen, D A, VanHasselt, P M, Weiss, M, Zwijnenburg, P, Sa, J, Reis, C F, López-Otín, C, Santiago-Fernández, O, Fernández-Jaén, A, Rauch, A, Steindl, K, Joset, P, Goldstein, A, Madan-Khetarpal, S, Infante, E, Zackai, E, Mcdougall, C, Narayanan, V, Ramsey, K, Undiagnosed Diseases Network, Davids, M, Sullivan, J A, Au, M, Pérez-Jurado, L A, Kleefstra, T, Penzes, P, Wood, S A, Burne, T, Pierson, T, Piper, M, Gecz, J & Jolly, L A 2020, ' Partial Loss of USP9X Function Leads to a Male Neurodevelopmental and Behavioral Disorder Converging on Transforming Growth Factor β Signaling ', Biological Psychiatry, vol. 87, no. 2, pp. 100-112 . https://doi.org/10.1016/j.biopsych.2019.05.028, Biol Psychiatry, Biological Psychiatry, 87(2), 100-112. ELSEVIER SCIENCE INC, Biological Psychiatry, 87(2), 100-112. Elsevier Inc., Biological Psychiatry, 87(2), 100-112. Elsevier USA, Biological Psychiatry, 87(2), 100-112. Elsevier Science
- Publication Year :
- 2020
-
Abstract
- Contains fulltext : 218305.pdf (Publisher’s version ) (Closed access) BACKGROUND: The X-chromosome gene USP9X encodes a deubiquitylating enzyme that has been associated with neurodevelopmental disorders primarily in female subjects. USP9X escapes X inactivation, and in female subjects de novo heterozygous copy number loss or truncating mutations cause haploinsufficiency culminating in a recognizable syndrome with intellectual disability and signature brain and congenital abnormalities. In contrast, the involvement of USP9X in male neurodevelopmental disorders remains tentative. METHODS: We used clinically recommended guidelines to collect and interrogate the pathogenicity of 44 USP9X variants associated with neurodevelopmental disorders in males. Functional studies in patient-derived cell lines and mice were used to determine mechanisms of pathology. RESULTS: Twelve missense variants showed strong evidence of pathogenicity. We define a characteristic phenotype of the central nervous system (white matter disturbances, thin corpus callosum, and widened ventricles); global delay with significant alteration of speech, language, and behavior; hypotonia; joint hypermobility; visual system defects; and other common congenital and dysmorphic features. Comparison of in silico and phenotypical features align additional variants of unknown significance with likely pathogenicity. In support of partial loss-of-function mechanisms, using patient-derived cell lines, we show loss of only specific USP9X substrates that regulate neurodevelopmental signaling pathways and a united defect in transforming growth factor beta signaling. In addition, we find correlates of the male phenotype in Usp9x brain-specific knockout mice, and further resolve loss of hippocampal-dependent learning and memory. CONCLUSIONS: Our data demonstrate the involvement of USP9X variants in a distinctive neurodevelopmental and behavioral syndrome in male subjects and identify plausible mechanisms of pathogenesis centered on disrupted transforming growth factor beta signaling and hippocampal function.
- Subjects :
- Male
0301 basic medicine
Brain malformation
Developmental Disabilities
INTERACTS
USP9X
Haploinsufficiency
in-vitro
CELL-MIGRATION
Deubiquitylating enzyme
Biology
Hippocampus
of-function mutations
Article
liquid facets
TGFβ
Mice
03 medical and health sciences
0302 clinical medicine
Neurodevelopmental disorder
TGF beta
Transforming Growth Factor beta
Intellectual Disability
Intellectual disability
medicine
Animals
Humans
Missense mutation
deubiquitinating enzyme
Biological Psychiatry
fam/usp9x
Neurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7]
Male Phenotype
medicine.disease
Phenotype
Hypotonia
030104 developmental biology
Female
medicine.symptom
Ubiquitin Thiolesterase
Neuroscience
030217 neurology & neurosurgery
Signal Transduction
Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Transforming growth factor
Subjects
Details
- ISSN :
- 00063223
- Database :
- OpenAIRE
- Journal :
- Biological Psychiatry, 87, 100-112, Biological Psychiatry, 87, 2, pp. 100-112, Johnson, B V, Kumar, R, Oishi, S, Alexander, S, Kasherman, M, Vega, M S, Ivancevic, A, Gardner, A, Domingo, D, Corbett, M, Parnell, E, Yoon, S, Oh, T, Lines, M, Lefroy, H, Kini, U, van Allen, M, Grønborg, S, Mercier, S, Küry, S B, Bézieau, S, Pasquier, L, Raynaud, M, Afenjar, A, Billette de Villemeur, T, Keren, B, Désir, J, van Maldergem, L, Marangoni, M, Dikow, N, Koolen, D A, VanHasselt, P M, Weiss, M, Zwijnenburg, P, Sa, J, Reis, C F, López-Otín, C, Santiago-Fernández, O, Fernández-Jaén, A, Rauch, A, Steindl, K, Joset, P, Goldstein, A, Madan-Khetarpal, S, Infante, E, Zackai, E, Mcdougall, C, Narayanan, V, Ramsey, K, Undiagnosed Diseases Network, Davids, M, Sullivan, J A, Au, M, Pérez-Jurado, L A, Kleefstra, T, Penzes, P, Wood, S A, Burne, T, Pierson, T, Piper, M, Gecz, J & Jolly, L A 2020, ' Partial Loss of USP9X Function Leads to a Male Neurodevelopmental and Behavioral Disorder Converging on Transforming Growth Factor β Signaling ', Biological Psychiatry, vol. 87, no. 2, pp. 100-112 . https://doi.org/10.1016/j.biopsych.2019.05.028, Biol Psychiatry, Biological Psychiatry, 87(2), 100-112. ELSEVIER SCIENCE INC, Biological Psychiatry, 87(2), 100-112. Elsevier Inc., Biological Psychiatry, 87(2), 100-112. Elsevier USA, Biological Psychiatry, 87(2), 100-112. Elsevier Science
- Accession number :
- edsair.doi.dedup.....c52fb15e212408556ad7f7895a16106b
- Full Text :
- https://doi.org/10.1016/j.biopsych.2019.05.028